JP7866687B2 - 置換ピペラジン誘導体の結晶およびその調製方法 - Google Patents

置換ピペラジン誘導体の結晶およびその調製方法

Info

Publication number
JP7866687B2
JP7866687B2 JP2025525056A JP2025525056A JP7866687B2 JP 7866687 B2 JP7866687 B2 JP 7866687B2 JP 2025525056 A JP2025525056 A JP 2025525056A JP 2025525056 A JP2025525056 A JP 2025525056A JP 7866687 B2 JP7866687 B2 JP 7866687B2
Authority
JP
Japan
Prior art keywords
crystal
crystal form
diffraction pattern
solvent
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2025525056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025536416A (ja
JP2025536416A5 (cg-RX-API-DMAC7.html
Inventor
劉兆軍
楚洪柱
朱▲ユウ▼沁
曹▲シン▼
魏用剛
孫毅
Original Assignee
康百達(四川)生物医薬科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 康百達(四川)生物医薬科技有限公司 filed Critical 康百達(四川)生物医薬科技有限公司
Publication of JP2025536416A publication Critical patent/JP2025536416A/ja
Publication of JP2025536416A5 publication Critical patent/JP2025536416A5/ja
Application granted granted Critical
Publication of JP7866687B2 publication Critical patent/JP7866687B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2025525056A 2022-11-14 2023-11-14 置換ピペラジン誘導体の結晶およびその調製方法 Active JP7866687B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202211417721.3 2022-11-14
CN202211417721 2022-11-14
PCT/CN2023/131627 WO2024104354A1 (zh) 2022-11-14 2023-11-14 一种取代的哌嗪衍生物的晶体及其制备方法

Publications (3)

Publication Number Publication Date
JP2025536416A JP2025536416A (ja) 2025-11-05
JP2025536416A5 JP2025536416A5 (cg-RX-API-DMAC7.html) 2026-04-10
JP7866687B2 true JP7866687B2 (ja) 2026-05-27

Family

ID=90997576

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025525056A Active JP7866687B2 (ja) 2022-11-14 2023-11-14 置換ピペラジン誘導体の結晶およびその調製方法

Country Status (9)

Country Link
US (1) US20250270223A1 (cg-RX-API-DMAC7.html)
EP (1) EP4620958A4 (cg-RX-API-DMAC7.html)
JP (1) JP7866687B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250086779A (cg-RX-API-DMAC7.html)
CN (1) CN118027039A (cg-RX-API-DMAC7.html)
AU (1) AU2023381502A1 (cg-RX-API-DMAC7.html)
MX (1) MX2025005591A (cg-RX-API-DMAC7.html)
TW (1) TWI879228B (cg-RX-API-DMAC7.html)
WO (1) WO2024104354A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL326495A (en) * 2023-08-17 2026-04-01 Kangbaida Sichuan Biotechnology Co Ltd Pharmaceutical preparation of piperazine derivative, preparation method therefor, and use thereof
WO2025209574A1 (zh) * 2024-04-03 2025-10-09 康百达(四川)生物医药科技有限公司 用于预防或治疗肿瘤的parp7抑制剂

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
CN112424188A (zh) 2018-04-30 2021-02-26 里邦医疗公司 作为parp7抑制剂的哒嗪酮
CN112745312A (zh) 2019-10-30 2021-05-04 沈阳中化农药化工研发有限公司 哒嗪酮异恶唑甲醚类化合物及其应用
WO2021087018A1 (en) 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
WO2022111700A1 (zh) 2020-11-27 2022-06-02 成都百裕制药股份有限公司 哒嗪酮衍生物及其在医药上的应用
WO2022156708A1 (en) 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Parp7 enzyme inhibitor
WO2022242750A1 (zh) 2021-05-21 2022-11-24 成都百裕制药股份有限公司 哌嗪衍生物及其在医药上的应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112424188A (zh) 2018-04-30 2021-02-26 里邦医疗公司 作为parp7抑制剂的哒嗪酮
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
CN112745312A (zh) 2019-10-30 2021-05-04 沈阳中化农药化工研发有限公司 哒嗪酮异恶唑甲醚类化合物及其应用
WO2021087018A1 (en) 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
WO2022111700A1 (zh) 2020-11-27 2022-06-02 成都百裕制药股份有限公司 哒嗪酮衍生物及其在医药上的应用
WO2022156708A1 (en) 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Parp7 enzyme inhibitor
WO2022242750A1 (zh) 2021-05-21 2022-11-24 成都百裕制药股份有限公司 哌嗪衍生物及其在医药上的应用

Also Published As

Publication number Publication date
EP4620958A1 (en) 2025-09-24
TWI879228B (zh) 2025-04-01
JP2025536416A (ja) 2025-11-05
AU2023381502A1 (en) 2025-05-15
US20250270223A1 (en) 2025-08-28
EP4620958A4 (en) 2026-08-05
KR20250086779A (ko) 2025-06-13
MX2025005591A (es) 2025-06-02
TW202426452A (zh) 2024-07-01
CN118027039A (zh) 2024-05-14
WO2024104354A1 (zh) 2024-05-23

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250530

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20260402

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260421

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260515

R150 Certificate of patent or registration of utility model

Ref document number: 7866687

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150